Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer's disease using conjoint univariate and independent component analyses.

Toussaint PJ, Perlbarg V, Bellec P, Desarnaud S, Lacomblez L, Doyon J, Habert MO, Benali H; Benali, for the Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Nov 1;63(2):936-46. doi: 10.1016/j.neuroimage.2012.03.091. Epub 2012 Apr 10.


Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease.

Mosconi L, Pupi A, De Cristofaro MT, Fayyaz M, Sorbi S, Herholz K.

J Nucl Med. 2004 Mar;45(3):382-92.


Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.


Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013. Epub 2010 Apr 10.


Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.

Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, Matsuda H, Mori E.

Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9. Epub 2006 Mar 21.


Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: an analysis of 3D PET data from J-ADNI, a multi-center study.

Takahashi R, Ishii K, Senda M, Ito K, Ishii K, Kato T, Makishi Y, Nishio T, Ikari Y, Iwatsubo T; Japanese Alzheimer’s Disease Neuroimaging Initiative.

Ann Nucl Med. 2013 Jun;27(5):452-9. doi: 10.1007/s12149-013-0704-x. Epub 2013 Mar 13.


Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.

Arbizu J, Prieto E, Martínez-Lage P, Martí-Climent JM, García-Granero M, Lamet I, Pastor P, Riverol M, Gómez-Isla MT, Peñuelas I, Richter JA, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1394-405. doi: 10.1007/s00259-013-2458-z. Epub 2013 May 29.


Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.

Furukawa K, Okamura N, Tashiro M, Waragai M, Furumoto S, Iwata R, Yanai K, Kudo Y, Arai H.

J Neurol. 2010 May;257(5):721-7. doi: 10.1007/s00415-009-5396-8. Epub 2009 Nov 28.


High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A.

Curr Alzheimer Res. 2010 Feb;7(1):56-66.


White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients.

Zhou Y, Yu F, Duong TQ; Alzheimer's Disease Neuroimaging Initiative.

J Magn Reson Imaging. 2015 Jan;41(1):102-9. doi: 10.1002/jmri.24550. Epub 2013 Dec 31.


18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis.

Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC.

J Cereb Blood Flow Metab. 2006 Sep;26(9):1213-21. Epub 2006 Mar 8.


Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A.

J Nucl Med. 2005 Oct;46(10):1625-32.


Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study.

Yakushev I, Schreckenberger M, Müller MJ, Schermuly I, Cumming P, Stoeter P, Gerhard A, Fellgiebel A.

Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2219-27. doi: 10.1007/s00259-011-1882-1. Epub 2011 Jul 27.


Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease.

Förster S, Buschert VC, Buchholz HG, Teipel SJ, Friese U, Zach C, la Fougere C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Buerger K.

J Alzheimers Dis. 2011;25(4):695-706. doi: 10.3233/JAD-2011-100996.


Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.

Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y.

Int J Clin Pract. 2012 Feb;66(2):185-98. doi: 10.1111/j.1742-1241.2011.02845.x. Review.


(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.

Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de Leon MJ.

J Nucl Med. 2007 Jul;48(7):1129-34. Epub 2007 Jun 15.


Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.


Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer's disease.

Musiek ES, Saboury B, Mishra S, Chen Y, Reddin JS, Newberg AB, Udupa JK, Detre JA, Hofheinz F, Torigian D, Alavi A.

Hell J Nucl Med. 2012 Sep-Dec;15(3):190-6. doi: 10.1967/s002449910052. Epub 2012 Oct 25.


[Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].

Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla J, Portilla-Quattrociocchi H, Medina-Quiroz P, Ortega F, Rodríguez E, Mateo I, Vázquez-Higuera JL, de Arcocha M, Carril JM.

Rev Esp Med Nucl. 2011 Sep-Oct;30(5):301-6. doi: 10.1016/j.remn.2011.03.010. Epub 2011 Jun 2. Spanish.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk